HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
GPSM2
G protein signaling modulator 2
Chromosome 1 Β· 1p13.3
NCBI Gene: 29899Ensembl: ENSG00000121957.16HGNC: HGNC:29501UniProt: B4DIF1
73PubMed Papers
21Diseases
0Drugs
37Pathogenic Variants
FUNCTIONAL ROLE
Transporter
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
cytosollateral cell cortexcytoplasmcell cortex regionChudley-McCullough syndromehearing loss, autosomal recessiveRare genetic deafnessdeafness
✦AI Summary

GPSM2 (G protein signaling modulator 2) is a critical regulator of cell division and polarity with primary functions in mitotic spindle organization and G protein signaling. It plays a central role in orienting the mitotic spindle via interaction with NUMA1 and recruitment of the cortical dynein-dynactin complex during metaphase, facilitating asymmetric cell divisions 12. GPSM2 functions as a guanine nucleotide dissociation inhibitor for GΞ±i proteins and localizes to stereocilia tips in hair cells, where it partners with GNAI3, MYO15A, and WHRN to specify tallest stereocilia and promote actin dynamics 34. Mutations in GPSM2 cause Chudley-McCullough syndrome, an autosomal recessive disorder characterized by sensorineural hearing loss and brain malformations including polymicrogyria and corpus callosum agenesis, reflecting defective asymmetric cell divisions during development 53. The GoLoco motifs are essential for hearing function and proper kinocilium positioning 6. Beyond genetic disease, GPSM2 dysregulation has emerging roles in cancer progression; reduced GPSM2 expression promotes lung adenocarcinoma proliferation via EGFR signaling 7. Additionally, truncated GPSM2 isoforms are upregulated in systemic lupus erythematosus CD4+ T cells, promoting migration and potentially contributing to organ infiltration 8. GPSM2 represents both a diagnostic/prognostic biomarker and potential therapeutic target across multiple disease contexts 9.

Sources cited
1
GPSM2 is required for cortical dynein-dynactin complex recruitment and plays a role in metaphase spindle orientation
PMID: 22327364
2
GPSM2 plays an important role in asymmetric cell divisions and mitotic spindle pole organization
PMID: 21816348
3
GPSM2 mutations cause Chudley-McCullough syndrome; GPSM2 regulates actin dynamics in stereocilia and neuronal growth cones via GΞ±i3
PMID: 28387217
4
GPSM2-GNAI complex localizes to stereocilia distal tips and is required for postnatal elongation, defining the tallest row identity in hair bundles
PMID: 30827920
5
GPSM2 mutations underlie Chudley-McCullough syndrome with sensorineural hearing loss and characteristic brain malformations including polymicrogyria and corpus callosum abnormalities
PMID: 22578326
6
GPSM2/LGN GoLoco motifs are essential for hearing; mutations cause hearing loss through misorientation of hair bundles and stereocilia malformations
PMID: 26662512
7
GPSM2 knockdown promotes lung adenocarcinoma cell proliferation via EGFR signaling pathway and serves as a prognostic biomarker
PMID: 32058048
8
Truncated GPSM2 isoforms containing GoLoco motifs are upregulated in SLE CD4+ T cells and promote T-cell migration toward CCL20
PMID: 35940821
9
GPSM2 is a potential pan-cancer diagnostic and prognostic biomarker with roles in tumor stemness and immunotherapy response
PMID: 40208185
Disease Associationsβ“˜21
Chudley-McCullough syndromeOpen Targets
0.79Strong
hearing loss, autosomal recessiveOpen Targets
0.59Moderate
Rare genetic deafnessOpen Targets
0.49Moderate
deafnessOpen Targets
0.49Moderate
genetic disorderOpen Targets
0.41Moderate
neurodegenerative diseaseOpen Targets
0.37Weak
breast-ovarian cancer, familial, susceptibility to, 2Open Targets
0.34Weak
gastric ulcerOpen Targets
0.18Weak
hemorrhageOpen Targets
0.18Weak
Hearing impairmentOpen Targets
0.12Weak
breast cancerOpen Targets
0.09Suggestive
neoplasmOpen Targets
0.09Suggestive
cystOpen Targets
0.08Suggestive
liver cancerOpen Targets
0.08Suggestive
non-small cell lung carcinomaOpen Targets
0.08Suggestive
cancerOpen Targets
0.07Suggestive
hepatocellular carcinomaOpen Targets
0.07Suggestive
retinitis pigmentosaOpen Targets
0.07Suggestive
Familial exudative vitreoretinopathyOpen Targets
0.06Suggestive
early-onset non-syndromic cataractOpen Targets
0.06Suggestive
Chudley-McCullough syndromeUniProt
Pathogenic Variants37
NM_013296.5(GPSM2):c.379C>T (p.Arg127Ter)Pathogenic
Chudley-McCullough syndrome|Hearing loss, autosomal recessive|Breast-ovarian cancer, familial, susceptibility to, 2
β˜…β˜…β˜†β˜†2025β†’ Residue 127
NM_013296.5(GPSM2):c.1062+1G>TPathogenic
Chudley-McCullough syndrome|not specified|not provided
β˜…β˜…β˜†β˜†2025
NM_013296.5(GPSM2):c.742del (p.Gly249fs)Pathogenic
Chudley-McCullough syndrome|not provided|Rare genetic deafness|GPSM2-related disorder
β˜…β˜…β˜†β˜†2025β†’ Residue 249
NM_013296.5(GPSM2):c.485del (p.Pro162fs)Pathogenic
not provided|Inborn genetic diseases
β˜…β˜…β˜†β˜†2025β†’ Residue 162
NM_013296.5(GPSM2):c.1492C>T (p.Arg498Ter)Pathogenic
Rare genetic deafness|not provided|Chudley-McCullough syndrome|GPSM2-related disorder
β˜…β˜…β˜†β˜†2024β†’ Residue 498
NM_013296.5(GPSM2):c.1063-1G>TPathogenic
Rare genetic deafness|not provided
β˜…β˜…β˜†β˜†2024
NM_013296.5(GPSM2):c.1661C>A (p.Ser554Ter)Pathogenic
Chudley-McCullough syndrome|not provided
β˜…β˜…β˜†β˜†2023β†’ Residue 554
NM_013296.5(GPSM2):c.1080_1081del (p.Glu361fs)Pathogenic
not provided
β˜…β˜…β˜†β˜†2023β†’ Residue 361
NM_013296.5(GPSM2):c.1473del (p.Phe492fs)Pathogenic
not provided|Rare genetic deafness|Chudley-McCullough syndrome|GPSM2-related disorder
β˜…β˜…β˜†β˜†2022β†’ Residue 492
NM_013296.5(GPSM2):c.1501del (p.Ser501fs)Pathogenic
Chudley-McCullough syndrome
β˜…β˜…β˜†β˜†2021β†’ Residue 501
NM_013296.5(GPSM2):c.557+2T>CLikely pathogenic
not provided
β˜…β˜…β˜†β˜†2021
NM_013296.5(GPSM2):c.1263+1G>TLikely pathogenic
not provided
β˜…β˜†β˜†β˜†2025
NM_013296.5(GPSM2):c.666_670dup (p.Ala224delinsValTer)Pathogenic
not provided
β˜…β˜†β˜†β˜†2025β†’ Residue 224
NM_013296.5(GPSM2):c.1093C>T (p.Arg365Ter)Pathogenic
not provided
β˜…β˜†β˜†β˜†2024β†’ Residue 365
NM_013296.5(GPSM2):c.1002del (p.Ala334_Leu335insTer)Pathogenic
Chudley-McCullough syndrome
β˜…β˜†β˜†β˜†2024β†’ Residue 334
NM_013296.5(GPSM2):c.1337_1338del (p.Phe446fs)Likely pathogenic
Chudley-McCullough syndrome|not provided
β˜…β˜†β˜†β˜†2024β†’ Residue 446
NM_013296.5(GPSM2):c.681+2delLikely pathogenic
not provided
β˜…β˜†β˜†β˜†2023
NM_013296.5(GPSM2):c.1055C>A (p.Ser352Ter)Likely pathogenic
Chudley-McCullough syndrome
β˜…β˜†β˜†β˜†2023β†’ Residue 352
NM_013296.5(GPSM2):c.998dup (p.Ala334fs)Pathogenic
not provided
β˜…β˜†β˜†β˜†2023β†’ Residue 334
NM_013296.5(GPSM2):c.1578del (p.Pro528fs)Likely pathogenic
Chudley-McCullough syndrome
β˜…β˜†β˜†β˜†2023β†’ Residue 528
View on ClinVar β†—
Related Genes
MYO15AProtein interaction100%GNAI2Protein interaction96%GNAI3Protein interaction96%DLG4Protein interaction96%EPS8Protein interaction95%WHRNProtein interaction95%
Tissue Expression6 tissues
Brain
100%
Bone Marrow
75%
Lung
31%
Ovary
15%
Liver
13%
Heart
9%
Gene Interaction Network
Click a node to explore
GPSM2MYO15AGNAI2GNAI3DLG4EPS8WHRN
PROTEIN STRUCTURE
Preparing viewer…
PDB4WND Β· 1.50 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.86LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF0.60 [0.43–0.86]
RankingsWhere GPSM2 stands among ~20K protein-coding genes
  • #6,466of 20,598
    Most Researched73
  • #1,623of 5,498
    Most Pathogenic Variants37
  • #7,532of 17,882
    Most Constrained (LOEUF)0.86
Genes detectedGPSM2
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
Comprehensive Analysis of GPSM2: From Pan-Cancer Analysis to Experimental Validation.
PMID: 40208185
J Cell Mol Med Β· 2025
1.00
2
Truncated isoforms of GPSM2 containing the GoLoco motif region promote CD4
PMID: 35940821
Lupus Sci Med Β· 2022
0.90
3
Defective Gpsm2/GΞ±
PMID: 28387217
Nat Commun Β· 2017
0.80
4
Loss of G-protein-signaling modulator 2 accelerates proliferation of lung adenocarcinoma via EGFR signaling pathway.
PMID: 32058048
Int J Biochem Cell Biol Β· 2020
0.70
5
GPSM2-GNAI Specifies the Tallest Stereocilia and Defines Hair Bundle Row Identity.
PMID: 30827920
Curr Biol Β· 2019
0.60